R 190Alternative Names: R-190
Latest Information Update: 21 Jul 2016
At a glance
- Originator Radikal Therapeutics
- Class Small molecules
- Mechanism of Action Nitric oxide donors; Reactive oxygen species inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bacteraemia; Bronchopulmonary dysplasia; Hypertension; Kidney disorders; Pulmonary arterial hypertension; Renal failure; Reperfusion injury